CRMD CorMedix Inc.

Nasdaq cormedix.com


$ 11.36 $ 0.53 (4.89 %)    

Friday, 14-Nov-2025 11:10:16 EST
QQQ $ 609.19 $ 9.63 (1.61 %)
DIA $ 471.80 $ 0.25 (0.05 %)
SPY $ 672.10 $ 6.65 (1 %)
TLT $ 89.17 $ -0.62 (-0.69 %)
GLD $ 375.69 $ 2.80 (0.75 %)
$ 11.21
$ 10.77
$ 11.39 x 293
$ 11.41 x 249
$ 10.77 - $ 11.41
$ 5.60 - $ 17.43
5,982,080
na
966.46M
$ 1.72
$ 5.95
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-12-2025 09-30-2025 10-Q
2 08-07-2025 06-30-2025 10-Q
3 05-06-2025 03-31-2025 10-Q
4 03-25-2025 12-31-2024 10-K
5 10-30-2024 09-30-2024 10-Q
6 08-14-2024 06-30-2024 10-Q
7 05-09-2024 03-31-2024 10-Q
8 03-12-2024 12-31-2023 10-K
9 11-14-2023 09-30-2023 10-Q
10 08-08-2023 06-30-2023 10-Q
11 05-15-2023 03-31-2023 10-Q
12 03-30-2023 12-31-2022 10-K
13 11-10-2022 09-30-2022 10-Q
14 08-11-2022 06-30-2022 10-Q
15 05-12-2022 03-31-2022 10-Q
16 03-29-2022 12-31-2021 10-K
17 11-09-2021 09-30-2021 10-Q
18 08-12-2021 06-30-2021 10-Q
19 05-13-2021 03-31-2021 10-Q
20 03-30-2021 12-31-2020 10-K
21 11-05-2020 09-30-2020 10-Q
22 08-10-2020 06-30-2020 10-Q
23 05-11-2020 03-31-2020 10-Q
24 03-16-2020 12-31-2019 10-K
25 11-14-2019 09-30-2019 10-Q
26 08-14-2019 06-30-2019 10-Q
27 05-13-2019 03-31-2019 10-Q
28 03-14-2019 12-31-2018 10-K
29 11-14-2018 09-30-2018 10-Q
30 08-14-2018 06-30-2018 10-Q
31 05-15-2018 03-31-2018 10-Q
32 03-19-2018 12-31-2017 10-K
33 11-09-2017 09-30-2017 10-Q
34 08-09-2017 06-30-2017 10-Q
35 05-10-2017 03-31-2017 10-Q
36 03-16-2017 12-31-2016 10-K
37 11-09-2016 09-30-2016 10-Q
38 08-04-2016 06-30-2016 10-Q
39 05-10-2016 03-31-2016 10-Q
40 03-15-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-maintains-buy-on-cormedix-raises-price-target-to-18

HC Wainwright & Co. analyst Brandon Folkes maintains Cormedix (NASDAQ:CRMD) with a Buy and raises the price target from ...

 d-boral-capital-maintains-buy-on-cormedix-maintains-14-price-target

D. Boral Capital analyst Jason Kolbert maintains Cormedix (NASDAQ:CRMD) with a Buy and maintains $14 price target.

 needham-maintains-buy-on-cormedix-lowers-price-target-to-16

Needham analyst Serge Belanger maintains Cormedix (NASDAQ:CRMD) with a Buy and lowers the price target from $20 to $16.

 cormedix-q3-profit-soars-as-defencath-dialysis-demand-exceeds-expectations

CorMedix posts strong Q3 results with $104 million in revenue, higher DefenCath sales, and raises 2025 guidance following Melin...

 cormedix-sees-fy2025-sales-390000m-410000m-vs-283692m-est

CorMedix again raises its full-year 2025 pro forma net revenue guidance to a range of $390 to $410 million, and fourth quarter ...

 cormedix-sees-q4-sales-115000m-135000m-vs-118847m-est

Cormedix (NASDAQ:CRMD) sees Q4 sales of $115.000 million-$135.000 million vs $118.847 million analyst estimate.

 cormedix-q3-eps-126-beats-063-estimate-sales-104270m-beat-86023m-estimate

Cormedix (NASDAQ:CRMD) reported quarterly earnings of $1.26 per share which beat the analyst consensus estimate of $0.63 by 100...

 top-stocks-with-earnings-this-week-plug-oklo-circle-and-more

Here's a look at this week's earnings reports that are most likely to be watched by retail investors, including Oklo, P...

 cormedix-says-defencath-receives-innovative-technology-designation-from-vizient

CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for lif...

 rbc-capital-maintains-outperform-on-cormedix-raises-price-target-to-22

RBC Capital analyst Leonid Timashev maintains Cormedix (NASDAQ:CRMD) with a Outperform and raises the price target from $21 ...

 d-boral-capital-upgrades-cormedix-to-buy-announces-14-price-target

D. Boral Capital analyst Jason Kolbert upgrades Cormedix (NASDAQ:CRMD) from Hold to Buy and announces $14 price target.

Core News & Articles

REPL: 81% | The FDA Accepts Replimune's Resubmission Of The Biologics License Application For RP1 In Combination With Nivol...

 cormedix-files-for-offering-of-up-to-63m-shares-of-common-stock-by-selling-securityholders

https://www.sec.gov/Archives/edgar/data/1410098/000121390025094067/ea0258874-s3_cormedix.htm

 cormedix-completes-enrollment-in-phase-iii-respect-trial-for-rezzayo-in-fungal-infection-prevention

- Enrollment Completed in Ongoing Phase III ReSPECT Study in Prophylaxis of Fungal Infections in Adult Patients Undergoing Allo...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION